Plus an evidence-backed look at how tirzepatide compares with semaglutide (Ozempic) for weight loss and Type 2 diabetes
| Key TakeawaysTirzepatide is the generic name of the drug; Mounjaro is the brand name sold by Eli Lilly. They are the same medicine, not two different ones.In the head-to-head SURMOUNT-5 trial, tirzepatide led to 20.2% weight loss versus 13.7% with semaglutide (the molecule in Ozempic and Wegovy) over 72 weeks.Mounjaro is now available in India through CDSCO-approved channels and may suit adults with Type 2 diabetes or obesity. Use is prescription-only and requires medical supervision. |
If you have been searching for a clear answer on tirzepatide, Mounjaro, Ozempic, and Wegovy, you are in the right place.
This guide untangles the brand-versus-generic confusion first, then walks through how tirzepatide actually compares with semaglutide on weight loss, diabetes control, side effects, and availability in India.
So Are Tirzepatide and Mounjaro the Same Thing?
Yes. Tirzepatide is the generic name of the active drug molecule. Mounjaro is the brand name used by Eli Lilly to sell tirzepatide for Type 2 diabetes. Asking “tirzepatide vs Mounjaro” is similar to asking “paracetamol vs Crocin” – one is the chemical, the other is the box it comes in.
The same molecule is sold under different brand names depending on the country and the medical use.
| Term | What It Is | Approved Use |
|---|---|---|
| Tirzepatide | The generic drug molecule (dual GIP and GLP-1 receptor agonist) | Type 2 diabetes; obesity / overweight with comorbidity |
| Mounjaro | Eli Lilly’s brand of tirzepatide (vial and KwikPen formats) | Type 2 diabetes and chronic weight management (India and several other markets) |
| Zepbound | Eli Lilly’s brand of tirzepatide (US market) | Chronic weight management and obstructive sleep apnoea in adults with obesity |
| Semaglutide | A different generic molecule (GLP-1 receptor agonist only) | Type 2 diabetes and chronic weight management |
| Ozempic | Novo Nordisk’s brand of semaglutide (injection) | Type 2 diabetes |
| Wegovy | Novo Nordisk’s brand of semaglutide (higher-dose injection) | Chronic weight management |
This is why most genuine clinical questions are not tirzepatide vs Mounjaro; they are tirzepatide vs semaglutide (the molecule inside Ozempic and Wegovy).
How Do Tirzepatide and Semaglutide Actually Work Inside the Body?
Both drugs belong to a class called incretin therapies, but they engage different gut hormone systems. Semaglutide acts on one receptor; tirzepatide acts on two.
Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a hormone the gut releases after meals.
The effect is slower stomach emptying, increased insulin release when blood sugar is high, and reduced appetite signals from the brain.
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It activates the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor at the same time.
According to a mechanism study published in JCI Insight, tirzepatide engages the GIP receptor more strongly than the GLP-1 receptor, which may explain why it can deliver larger metabolic effects at lower receptor occupancy.
In simpler terms: GLP-1 alone is a strong signal that tells the body to use insulin better and eat less. Adding GIP appears to compound the effect on insulin sensitivity and fat metabolism, which is why head-to-head trials have shown larger reductions in weight and HbA1c with tirzepatide.
| Feature | Tirzepatide (Mounjaro) | Semaglutide (Ozempic / Wegovy) |
|---|---|---|
| Drug class | Dual GIP + GLP-1 receptor agonist | GLP-1 receptor agonist (single) |
| Receptors activated | Two (GIP and GLP-1) | One (GLP-1) |
| Dosing frequency | Once weekly injection | Once weekly injection (Ozempic, Wegovy); daily oral tablet (Rybelsus) |
| Available doses (injectable) | 2.5, 5, 7.5, 10, 12.5, 15 mg | 0.25, 0.5, 1, 2 mg (Ozempic); up to 2.4 mg (Wegovy) |
| Manufacturer | Eli Lilly | Novo Nordisk |
Which One Causes More Weight Loss?
In the first direct head-to-head trial between the two molecules, tirzepatide led to about 47% more average weight loss than semaglutide.
The SURMOUNT-5 trial, published in The New England Journal of Medicine in 2025, randomly assigned 751 adults with obesity (or overweight with a related condition) and without Type 2 diabetes to receive maximum tolerated doses of either drug for 72 weeks.
At the end of the trial, average body weight reduction was 20.2% with tirzepatide versus 13.7% with semaglutide. In absolute terms, that worked out to roughly 22.8 kg of weight lost with tirzepatide versus 15.0 kg with semaglutide, according to the American College of Cardiology review of the trial.
The gap widened further among people who lost the most weight. About 31.6% of participants on tirzepatide achieved at least 25% body weight reduction, compared with 16.1% on semaglutide.
| SURMOUNT-5 Outcome (72 weeks) | Tirzepatide | Semaglutide |
|---|---|---|
| Mean body weight reduction | 20.2% | 13.7% |
| Absolute average weight lost | 22.8 kg | 15.0 kg |
| Participants with ≥10% weight loss | Significantly higher | Lower |
| Participants with ≥15% weight loss | Significantly higher | Lower |
| Participants with ≥20% weight loss | Significantly higher | Lower |
| Participants with ≥25% weight loss | 31.6% | 16.1% |
It is worth noting that SURMOUNT-5 was an open-label trial funded by Eli Lilly, the maker of tirzepatide. The participants and investigators knew which drug was being given.
That does not invalidate the results, since they were peer-reviewed and published in the most rigorous medical journal, but it is a context worth keeping in mind.
Which One Works Better for Type 2 Diabetes?
On blood sugar control, tirzepatide has also outperformed semaglutide head-to-head. The SURPASS-2 trial, also published in The New England Journal of Medicine, randomised 1,879 adults with Type 2 diabetes (inadequately controlled on metformin) to one of three tirzepatide doses or to semaglutide 1 mg.
After 40 weeks, all three tirzepatide doses produced greater HbA1c reduction and greater weight loss than semaglutide:
| SURPASS-2 Outcome (40 weeks) | Tirzepatide 5 mg | Tirzepatide 10 mg | Tirzepatide 15 mg | Semaglutide 1 mg |
|---|---|---|---|---|
| HbA1c reduction from baseline | −2.01% | −2.24% | −2.30% | −1.86% |
| Average weight change | −7.6 kg | −9.3 kg | −11.2 kg | −5.7 kg |
A post-hoc analysis published in Diabetologia further showed that tirzepatide helped a larger share of participants hit composite targets — HbA1c below 6.5% combined with at least 10% weight loss — than semaglutide did at the dose used in the trial.
That said, the diabetes picture has nuances worth keeping in mind. Semaglutide currently has more mature cardiovascular outcome data.
The SELECT trial in over 17,000 adults with established cardiovascular disease and obesity (without diabetes) showed that semaglutide reduced major adverse cardiovascular events by about 20% compared with placebo over nearly 40 months.
Tirzepatide’s first major cardiovascular outcomes trial, SURPASS-CVOT, showed cardiovascular non-inferiority compared with dulaglutide (another GLP-1 drug).
Long-term data on tirzepatide’s effect on heart attacks and strokes is still maturing, with the SURMOUNT-MMO outcomes trial ongoing. For someone with diabetes plus a history of heart disease, this is a conversation worth having with a treating physician.
How Do the Side Effects Compare Between the Two?
Both drugs share the same family of side effects, since both rely on GLP-1 receptor activity. The most common issues are gastrointestinal: nausea, diarrhoea, constipation, vomiting, and reduced appetite.
Most are mild to moderate, appear during dose escalation, and tend to settle over time.
In SURMOUNT-5, overall side effect profiles were similar, but the rate of treatment discontinuation due to gastrointestinal events was actually lower with tirzepatide: 2.7% with tirzepatide versus 5.6% with semaglutide, per the trial publication in NEJM.
| Side effect category | Tirzepatide | Semaglutide |
|---|---|---|
| Nausea (most common) | Common (up to 24–33% across trials) | Common (similar range) |
| Diarrhoea | Common (17–23%) | Common |
| Constipation | Common (11–17%) | Common |
| Vomiting | 6–13% | Similar range |
| GI-related discontinuation (SURMOUNT-5) | 2.7% | 5.6% |
| Serious adverse events (SURMOUNT-5) | 4.8% | 3.5% |
| Injection site reactions | Slightly more common (1.9–4.5%) | Less common (around 0.2%) |
A separate post-marketing case series in PMC has flagged less common reactions, including palpitations, musculoskeletal pain, and headaches with tirzepatide.
Rates of severe events such as acute pancreatitis or gallbladder disease have remained low (≤1%) across both drugs in clinical trials, though gallbladder-related events have signalled slightly higher with semaglutide in some meta-analyses.
Anyone on either drug should report new symptoms to their treating clinician early, especially severe abdominal pain, persistent vomiting, or signs of dehydration.
Is Mounjaro Available in India, and What About Ozempic?
Yes. Mounjaro launched in India in March 2025, after approval by the Central Drugs Standard Control Organisation (CDSCO), as reported by Business Standard. It is approved as a prescription-only treatment, used alongside diet and physical activity, for:
- Adults with Type 2 diabetes whose blood sugar is not adequately controlled
- Adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related condition such as high blood pressure, dyslipidaemia, or obstructive sleep apnoea
Mounjaro is sold in two formats in India. The vial format launched first, in 2.5 mg and 5 mg strengths.
The easier-to-use KwikPen prefilled pen received CDSCO approval in June 2025 and was rolled out across all six dose strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg), per the BioSpectrum India launch announcement.
For semaglutide, the situation in India is more layered:
- Ozempic (injectable semaglutide) for Type 2 diabetes is approved internationally; commercial availability in India has been delayed, and Novo Nordisk’s Wegovy launched in India in mid-2025 for weight management.
- Rybelsus (oral semaglutide) tablets are available in India for Type 2 diabetes and have been on the market for some time.
Both Mounjaro and Wegovy are prescription-only medications in India. They are not approved for cosmetic weight loss in people without a clinical indication, and self-administration without medical supervision is not advised.
India’s diabetes and obesity burden, documented in the ICMR-INDIAB-23 national study, makes appropriate, supervised use particularly important.
Can Someone Switch from Ozempic to Mounjaro for Better Results?
Switching may be appropriate in some cases, but the decision should be made with a treating clinician — not based on social media or anecdotal reports.
Real-world evidence does suggest that switching from a GLP-1 drug like semaglutide to tirzepatide can lead to additional benefits for some people.
In a real-world analysis published in PMC, patients who switched from semaglutide to tirzepatide saw further HbA1c reduction over 12 weeks. Weight loss tends to follow a similar pattern in clinical practice. A separate Nature Medicine 2025 analysis of nearly 300,000 patients in routine care also found differences in cardiovascular outcomes between the two drugs that may matter depending on the individual’s risk profile.
A clinician will usually consider:
- How well current treatment is working (HbA1c, weight, side effects)
- Personal cardiovascular and metabolic history, including past heart attack or stroke
- Tolerability of GI side effects at current doses
- Access and supply of each drug in the country
- Cost considerations and treatment plans (handled outside the scope of this article)
Switching usually involves a dose-matching protocol rather than starting from scratch, and side effects often need to be re-evaluated during the first few weeks on the new drug.
| Bottom LineTirzepatide and Mounjaro are the same drug — one is the generic name, the other is Eli Lilly’s brand. The clinical comparison most people are actually looking for is between tirzepatide and semaglutide (Ozempic / Wegovy).In head-to-head trials, tirzepatide has produced greater weight loss (20.2% vs 13.7%) and greater HbA1c reduction than semaglutide, with a similar side effect profile and slightly fewer treatment-ending GI events.Mounjaro is approved and available in India, but it is a prescription-only medication. Any decision to start, switch, or stop these drugs should be made with a qualified clinician who can assess individual risk, side effects, and long-term goals. |
Frequently Asked Questions
Which causes more weight loss, tirzepatide or Ozempic?
In the SURMOUNT-5 head-to-head trial published in 2025, tirzepatide led to 20.2% average weight loss over 72 weeks compared with 13.7% with semaglutide (the molecule in Ozempic and Wegovy).
Tirzepatide also helped a larger share of participants reach ≥25% weight reduction. Individual response varies, and a qualified clinician is the right person to decide which drug suits each case.
Which drug is better for Type 2 diabetes, tirzepatide or semaglutide?
For HbA1c reduction and weight loss in Type 2 diabetes, the SURPASS-2 trial showed all three doses of tirzepatide produced greater reductions than semaglutide 1 mg.
Semaglutide, however, has more mature long-term cardiovascular outcome data, which can matter for people with established heart disease. Treatment choice should be individualised with a treating physician.
Can I switch from Ozempic to Mounjaro for better results?
Switching may be appropriate in some cases and real-world data suggest additional weight and HbA1c benefit for some people who switch.
However, the decision should be made with a treating clinician who can review current control, side effects, cardiovascular history, and dose-matching protocols. Self-switching without medical supervision is not advised.
Is Mounjaro the same as Ozempic?
No. Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist made by Eli Lilly. Ozempic contains semaglutide, a single GLP-1 receptor agonist made by Novo Nordisk.
They are in the same broad class (incretin therapies) but are different molecules with different effects on weight and HbA1c.
Is tirzepatide available in India?
Yes. Tirzepatide is sold in India under the brand name Mounjaro, approved by the CDSCO. It launched in vial form in March 2025 and in KwikPen format from mid-2025, with all six dose strengths available.
It is a prescription-only medication for Type 2 diabetes or chronic weight management and is not approved for cosmetic weight loss.
Medical Disclaimer
This article is for general informational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Tirzepatide, semaglutide, and related drugs are prescription medications. Anyone considering, starting, switching, or stopping these treatments should consult a qualified healthcare professional who can evaluate individual health status, family history, current medications, and long-term goals.
